Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial

Umanzor, J. Ventura; Aguiluz, M.; Pineda, C.; Andrade, Silvia Franco; Erazo, M.; Flores, Claudio; Santillana, Sergio

doi:10.1016/j.ygyno.2005.07.132

Cited by 46 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However; previous study using weekly cisplatin 40mg/m 2 had reported ototoxicity in 10% 15 while nephrotoxicity occurred in 42.9% in a study using weekly combination of gemcitabine with this standard dose of cisplatin. 16 Among hematologic toxicity; anemia was the most common (35.5%) followed by thrombocytopenia (31%) then neutropenia (26.6%) with grade 3 in 4.4% and no grade 4 that comparable to finding by Umanzor et al 6 However; Zarba et al 5 recorded grade 4 neutropenia in 4%. Anemia was found in 50% of patients treated with gemcitabine 125mg/m 2 and cisplatin 40mg/m 2 .…”

Section: Discussionsupporting

confidence: 53%

“…[4][5][6] Gemcitabine is activated intracellulary by deoxycytidine kinase and is converted into two active metabolites gemcitabine diphosphate and triphosphate which target DNA and RNA. It is considered to be an attractive compound to combine with ionizing radiation for several reasons: 1) It may inhibit repair of the DNA damage caused by radiation leading to increased cell death; 2) It may induce cell redistribution causing cells to accumulate in more radiosensitive phase of cell cycle; 3) Increased the radiosensitvity of hypoxic cells due to tumor shrinkage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

El-Hadaad

Wahba

Roshdy

et al. 2015

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

Original ArticleAbstract Purpose: This study was done to evaluate response, compliance and survival of weekly low dose cisplatin (20 mg/m 2 ) and gemcitabine (125 mg/m 2 ) concurrently with pelvic radiation as primary treatment of stage IIB-IIIB cervical cancer. Methods: External radiation consisted of 50 Gy/25 fractions using 6-10 MV photon followed by 600 cGy boost to parametrium if it was still felt thickened. Then, intracavitary radiotherapy to deliver 60 Gy at point A. Chemotherapy consisted of gemcitabine at a dose of 125 mg /m 2 was given by i.v infusion over 30 minutes immediately after cisplatin 20 mg /m 2 weekly for 5 weeks during EBRT. Fortyfive eligible patients received the treatment protocol. Results: Toxicity was tolerable and manageable. No grade 4 toxicity while grade 3 was recorded in hematologic one only. In order of frequency; diarrhea, nausea and vomiting, and anemia (50%, 40%, 35.5%) were most common adverse events. Overall clinical response rate was 93.4% with pathological complete response of 62.2%. After median follow-up of 20 months, 2-year survival and progression-free survival rates were 90.5% and 81% respectively. Conclusion: Weekly combination of low-dose cisplatin and gemcitabine given concurrently with pelvic radiotherapy in primary treatment of locally advanced cervical cancer resulted in a high response rate with a good compliance. Further exploration is needed for the use of this approach prior to incorporating it into routine clinical care through phase III clinical trial.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

El-Hadaad

Wahba

Roshdy

et al. 2015

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

show abstract

“…In this study, there were no significant correlations between PLN failure and chemotherapy. However, several researchers have tested new drugs for radiosensitizing chemotherapy, such as concurrent cisplatin/paclitaxel or cisplatin/gemcitabine chemoradiation for locally advanced cervical cancer [6,7]. In addition, several molecular targeting agents are being used for cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Strategies for novel treatment of locally advanced tumors include use of other drugs in the form of radiosensitizing chemotherapy [6][7][8], increasing the irradiation dose to improve the effect of the brachytherapy [9][10][11], and use of particle therapy [12]. These methods are expected to achieve better outcomes for locally advanced cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Impact of Boost Irradiation on Pelvic Lymph Node Control in Patients with Cervical Cancer

Wakatsuki¹,

Ohno

Kato

et al. 2012

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Radiation therapy (RT) for metastatic pelvic lymph nodes (PLNs) is not well established in cervical cancer. In this study the correlation between size of lymph nodes and control doses of RT was analyzed. Between January 2002 and December 2007, 245 patients with squamous cell carcinoma of the cervix treated with a combination of external beam irradiation with or without boost irradiation and high-dose rate brachytherapy were investigated. Size of lymph node was measured by computed tomography before RT and just after 50 Gy RT. Of the 245 patients, 78 had PLN metastases, and a total of 129 had enlarged PLNs diagnosed as metastases; 22 patients had PLN failure. The PLN control rate at 5 years was 79.5% for positive cases and 95.8% for negative cases. In cases with positive PLNs, 12 of 129 nodes (9.3%) developed recurrences. There was significant correlation between PLN control rate and size of PLN after 50 Gy (<10 mm: 96.7%, 10 mm: 75.7 % (P<0.001)). In addition, the recurrence in these poor-response nodes was significantly correlated with dose of RT. Nine of 16 nodes receiving ≤ 58 Gy had recurrence, but none of 21 nodes receiving > 58 Gy had recurrence (P = 0.0003). These results suggested that the response of lymph nodes after RT was a more significant predictive factor for recurrence than size of lymph node before RT, and poor-response lymph nodes might require boost irradiation at a total dose of > 58 Gy.

show abstract

“…Moreover, co-infection with Chlamydia trachomatis, herpes simplex virus type-2, immunosuppression and certain dietary deficiencies are other probable cofactors [3]. In medical case of cervical cancer, there are several methods of treatment, such as surgery [4,5], chemotherapy (hormone), radiotherapy or various combination methods [6][7][8][9]. However, the death rate of cervical cancer is still high [10].…”

Section: Introductionmentioning

confidence: 99%

Proteomic Analysis of Candidate Prognostic Urinary Marker for Cervical Cancer

Aobchey¹

2013

J Proteomics Bioinform

View full text Add to dashboard Cite

Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial

Cited by 46 publications

References 23 publications

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

Concurrent pelvic radiation with weekly low-dose cisplatin and gemcitabine as primary treatment of locally advanced cervical cancer: A phase II study

Impact of Boost Irradiation on Pelvic Lymph Node Control in Patients with Cervical Cancer

Proteomic Analysis of Candidate Prognostic Urinary Marker for Cervical Cancer

Contact Info

Product

Resources

About